1. 1 European Agency for the Evaluation of Medicinal Products, and Human Medicines Evaluation Unit ; Note for guidance on virus validation studies: the design contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95
2. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion
3. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient
4. 4 European Agency for the Evaluation of Medicinal Products; Human Medicines Evaluation Unit : CPMP Position Statement on CJD and plasma-derived and urine-derived medicinal products (20 February 2003). CPMP/BWP/2879/02
5. 5 French Agency for the Safety of Health Products : Evaluation of the Risk of Transmission of New Variant Creutzfeldt-Jakob Disease by Blood and Blood Components - Recommendations dated 11 December 2000. Synthesis report: Revision of measures to reduce the risk of transmission of TSE agents by blood products (updated in February 2002). Analysis of the transmission of Creutzfeldt-Jakob disease by human derived medicines and labile blood products (Update of report data from the ad hoc group December 2000) February report 2004